JP2008513485A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008513485A5 JP2008513485A5 JP2007532545A JP2007532545A JP2008513485A5 JP 2008513485 A5 JP2008513485 A5 JP 2008513485A5 JP 2007532545 A JP2007532545 A JP 2007532545A JP 2007532545 A JP2007532545 A JP 2007532545A JP 2008513485 A5 JP2008513485 A5 JP 2008513485A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- compound
- optionally substituted
- alkyl
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 11
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000002837 carbocyclic group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical class C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 6
- 239000002841 Lewis acid Substances 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 5
- 150000007517 lewis acids Chemical class 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 150000001412 amines Chemical class 0.000 claims 4
- -1 carbocycle Chemical group 0.000 claims 4
- 230000000813 microbial effect Effects 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical class C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 150000003235 pyrrolidines Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229910052720 vanadium Inorganic materials 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- NIWIKUAWVYZYBD-UHFFFAOYSA-N 3h-dithiazol-4-amine Chemical compound NC1=CSSN1 NIWIKUAWVYZYBD-UHFFFAOYSA-N 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- JJSKFMMFEZVDRS-UHFFFAOYSA-N N1C=CC=C1.NP1SSP1 Chemical compound N1C=CC=C1.NP1SSP1 JJSKFMMFEZVDRS-UHFFFAOYSA-N 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- 229910052787 antimony Inorganic materials 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 229910052785 arsenic Inorganic materials 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 229910021480 group 4 element Inorganic materials 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 CC(*C=CN=C1C)=CC=C1I Chemical compound CC(*C=CN=C1C)=CC=C1I 0.000 description 20
- UZUMHXJDXINXJT-UHFFFAOYSA-N CC(N(CC1)CCN1c(cc1)nc(N(c2ccccc2N2C)C2=C2C(NCCN3CCCC3)=O)c1C2=O)=O Chemical compound CC(N(CC1)CCN1c(cc1)nc(N(c2ccccc2N2C)C2=C2C(NCCN3CCCC3)=O)c1C2=O)=O UZUMHXJDXINXJT-UHFFFAOYSA-N 0.000 description 1
- WMFHZGKRSJVEKA-UHFFFAOYSA-N CCN1C(CCNC(C2=C3Sc(ccc(Cl)c4)c4N3c(nc(cc3)N(CC4)CC4c4nccnc4)c3C2=O)=O)CCC1 Chemical compound CCN1C(CCNC(C2=C3Sc(ccc(Cl)c4)c4N3c(nc(cc3)N(CC4)CC4c4nccnc4)c3C2=O)=O)CCC1 WMFHZGKRSJVEKA-UHFFFAOYSA-N 0.000 description 1
- KJFAWEQQSCAKGS-UHFFFAOYSA-N NC(CC1)CN1c(c(F)c1)nc(N(c(cccc2)c2S2)C2=C2C(NCCN3CCCC3)=O)c1C2=O Chemical compound NC(CC1)CN1c(c(F)c1)nc(N(c(cccc2)c2S2)C2=C2C(NCCN3CCCC3)=O)c1C2=O KJFAWEQQSCAKGS-UHFFFAOYSA-N 0.000 description 1
- IALKVGMLLDHBRY-XCVCLJGOSA-N O=C(/C=C/CCN1CCCC1)C1=C2Sc(cccc3)c3N2c(nc(N2CCCC2)nc2)c2C1=O Chemical compound O=C(/C=C/CCN1CCCC1)C1=C2Sc(cccc3)c3N2c(nc(N2CCCC2)nc2)c2C1=O IALKVGMLLDHBRY-XCVCLJGOSA-N 0.000 description 1
- XBAGFKNPGOFRSS-UHFFFAOYSA-N O=C(C(C(c1c2)=O)=C3Sc(cccc4)c4N3c1cc(SCCc1nccnc1)c2F)NCCN1CCCC1 Chemical compound O=C(C(C(c1c2)=O)=C3Sc(cccc4)c4N3c1cc(SCCc1nccnc1)c2F)NCCN1CCCC1 XBAGFKNPGOFRSS-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61103004P | 2004-09-17 | 2004-09-17 | |
| US63860304P | 2004-12-22 | 2004-12-22 | |
| US68879605P | 2005-06-09 | 2005-06-09 | |
| US68898605P | 2005-06-09 | 2005-06-09 | |
| US11/149,007 US7652134B2 (en) | 2004-09-17 | 2005-06-09 | Methods for converting quinolone esters into quinolone amides |
| PCT/US2005/033323 WO2006034113A2 (en) | 2004-09-17 | 2005-09-16 | Quinolone analogs as cell proliferation inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008513485A JP2008513485A (ja) | 2008-05-01 |
| JP2008513485A5 true JP2008513485A5 (cg-RX-API-DMAC7.html) | 2008-10-30 |
Family
ID=35735203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007532545A Ceased JP2008513485A (ja) | 2004-09-17 | 2005-09-16 | キノロンアナログ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7816406B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1802306A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008513485A (cg-RX-API-DMAC7.html) |
| KR (1) | KR100989029B1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005286965B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0515319A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2580749C (cg-RX-API-DMAC7.html) |
| IL (1) | IL181857A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007003282A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ553746A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006034113A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1928887B1 (en) | 2005-08-05 | 2014-12-17 | Senhwa Biosciences, Inc. | Methods of preparing quinolone analogs |
| WO2007146813A2 (en) * | 2006-06-08 | 2007-12-21 | Cylene Pharmaceuticals, Inc. | Pyridinone analogs as cell proliferation inhibitors |
| WO2007146831A2 (en) * | 2006-06-08 | 2007-12-21 | Cylene Pharmaceuticals, Inc. | Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide |
| PL2061765T3 (pl) | 2006-09-01 | 2015-04-30 | Senhwa Biosciences Inc | Modulatory białkowych kinaz serynowo-treoninowych i PARP |
| CN101801190A (zh) * | 2007-06-22 | 2010-08-11 | 赛林药物股份有限公司 | 治疗异常细胞增殖性疾病的方法 |
| US20080318939A1 (en) * | 2007-06-22 | 2008-12-25 | Whitten Jeffrey P | Methods for treating ophthalmic disorders |
| WO2009097014A2 (en) * | 2007-08-31 | 2009-08-06 | Cylene Pharmaceuticals, Inc. | Therapeutic kinase modulators |
| EP2201010B1 (en) | 2007-09-14 | 2013-11-06 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| JP5824213B2 (ja) * | 2007-10-05 | 2015-11-25 | センワ バイオサイエンシズ インコーポレイテッド | キノロン類似体およびそれに関連する方法 |
| WO2011031745A1 (en) | 2009-09-09 | 2011-03-17 | Achaogen, Inc. | Antibacterial fluoroquinolone analogs |
| RU2435758C1 (ru) * | 2010-07-19 | 2011-12-10 | Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) | Способ получения этилового эфира 3-оксо-3-(2,6-дихлорпиридин-3-ил) пропановой кислоты |
| CN106459068B (zh) | 2014-05-09 | 2019-01-22 | 皮梅拉股份有限公司 | 新组合物、用途和制备它们的方法 |
| US9758518B2 (en) | 2015-03-04 | 2017-09-12 | Pimera, Inc. | Compositions, uses and methods for making them |
| WO2016137471A1 (en) * | 2015-02-26 | 2016-09-01 | Nantpharma, Llc | Method for enhanced heparin quality |
| TWI730013B (zh) | 2015-11-20 | 2021-06-11 | 生華生物科技股份有限公司 | 用於治療癌症的四環喹諾酮類似物組合療法 |
| US9957282B2 (en) | 2015-12-14 | 2018-05-01 | Senhwa Biosciences, Inc. | Crystalline forms of quinolone analogs and their salts |
| CN108699083A (zh) * | 2015-12-14 | 2018-10-23 | 生华生物科技股份有限公司 | 喹啉酮类似物及其盐的结晶形式 |
| CN115583948A (zh) | 2017-03-28 | 2023-01-10 | 皮梅拉股份有限公司 | Pol1抑制剂的新型晶体形式 |
| WO2019168688A2 (en) | 2018-02-15 | 2019-09-06 | Senhwa Biosciences, Inc. | Quinolone analogs and their salts, compositions, and method for their use |
| JP2020189888A (ja) * | 2020-08-28 | 2020-11-26 | センワ バイオサイエンシズ インコーポレイテッド | キノロン類似体及びその塩の結晶形 |
| WO2025114459A1 (en) * | 2023-11-28 | 2025-06-05 | Genome Therapeutics Ltd | Tetracyclic compounds for use in antibody-drug conjugates for the treatment of cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2808070A1 (de) * | 1978-02-24 | 1979-08-30 | Bayer Ag | Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten |
| EP0058392B1 (en) * | 1981-02-18 | 1985-11-21 | Nippon Shinyaku Company, Limited | Substituted carboxylic acid derivatives |
| ZA852769B (en) * | 1984-04-26 | 1985-11-27 | Abbott Lab | Benzothiazolo-quinoline antibacterial compounds |
| ZA852802B (en) * | 1984-04-26 | 1985-11-27 | Abbott Lab | Benzoxazolo-quinoline antibacterial compounds |
| US4528285A (en) * | 1984-04-26 | 1985-07-09 | Abbott Laboratories | Methylenedioxy quino-benzothiazine derivatives |
| WO1989012055A1 (fr) | 1988-06-08 | 1989-12-14 | Kyorin Pharmaceutical Co., Ltd. | Agent antitumoral |
| US4959363A (en) * | 1989-06-23 | 1990-09-25 | Sterling Drug Inc. | Quinolonecarboxamide compounds, their preparation and use as antivirals. |
| IE912902A1 (en) | 1990-08-24 | 1992-02-26 | Abbott Lab | Quinbenzoxazine, quinobenzothiazine, and pyrido-acridine¹antineoplastic agents |
| JPH04117388A (ja) * | 1990-09-07 | 1992-04-17 | Hokuriku Seiyaku Co Ltd | チアゾロキノリン―４―カルボン酸誘導体 |
| US5646163A (en) * | 1992-10-30 | 1997-07-08 | The Procter & Gamble Company | Quinolone 5-(N-heterosubstituted amino) antimicrobials |
| GB9402275D0 (en) * | 1994-02-07 | 1994-03-30 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| US6559145B2 (en) * | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| US6699989B1 (en) * | 2000-08-28 | 2004-03-02 | B. Vithal Shetty | Antiviral and antimicrobial guanidine or biguanidine derivatives |
| JP2004515548A (ja) * | 2000-12-14 | 2004-05-27 | ザ プロクター アンド ギャンブル カンパニー | 抗微生物キノロン |
| US6821969B2 (en) * | 2001-02-13 | 2004-11-23 | Pharmacia & Upjohn Company | Thioxazinoquinolones as antiviral agents |
| US6900224B2 (en) | 2002-07-31 | 2005-05-31 | The Procter & Gamble Company | Antimicrobial quinolones, their compositions and uses |
| KR100944600B1 (ko) | 2003-04-07 | 2010-02-25 | 사일린 파마슈티칼스, 인크 | 치환된 퀴노벤족사진 유사체 |
| DE602005018333D1 (de) | 2004-03-15 | 2010-01-28 | Sunesis Pharmaceuticals Inc | Sns-595 und anwendungsverfahren |
-
2005
- 2005-09-16 EP EP05813754A patent/EP1802306A2/en not_active Withdrawn
- 2005-09-16 MX MX2007003282A patent/MX2007003282A/es not_active Application Discontinuation
- 2005-09-16 KR KR1020077008765A patent/KR100989029B1/ko not_active Expired - Fee Related
- 2005-09-16 NZ NZ553746A patent/NZ553746A/en not_active IP Right Cessation
- 2005-09-16 WO PCT/US2005/033323 patent/WO2006034113A2/en not_active Ceased
- 2005-09-16 AU AU2005286965A patent/AU2005286965B2/en not_active Expired
- 2005-09-16 US US11/228,636 patent/US7816406B2/en active Active
- 2005-09-16 JP JP2007532545A patent/JP2008513485A/ja not_active Ceased
- 2005-09-16 CA CA2580749A patent/CA2580749C/en not_active Expired - Lifetime
- 2005-09-16 BR BRPI0515319-0A patent/BRPI0515319A/pt not_active IP Right Cessation
-
2007
- 2007-03-12 IL IL181857A patent/IL181857A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008513485A5 (cg-RX-API-DMAC7.html) | ||
| RU2336275C2 (ru) | Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция | |
| HUP0401729A2 (hu) | IV típusú foszfodiészteráz inhibitor hatású alkin-aril-naftiridin-4(1H)-on-származékok és ezeket tartalmazó gyógyszerkészítmények | |
| JP2013509392A5 (cg-RX-API-DMAC7.html) | ||
| NO2015020I2 (no) | Ceritinib eller et farmasøytisk akseptabelt salt derav | |
| CA2475434A1 (en) | Aromatic amino acid derivatives and medicinal compositions | |
| JP2015510886A5 (cg-RX-API-DMAC7.html) | ||
| HUP0202263A2 (hu) | Benzimidazol-, indol- és imidazo-piridin-származékok és ezeket tartalmazó gyógyszerkészítmények | |
| MEP9208A (en) | Quinoline derivatives and their use as mycobacterial inhibitors | |
| WO2020113213A3 (en) | Cyclic pantetheine derivatives and uses thereof | |
| ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
| CY1111980T1 (el) | Παραγωγα του αμιδιου τα οποια φερουν ενα υποκαταστατο του κυκλοπροπυλαμινοκαρβονυλιου και χρησιμευουν ως αναστολεις κυτταροκινης | |
| NO20091858L (no) | Hydrobenzamid derivater som inhibitorer av HSP90 | |
| BR0207846A (pt) | Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas | |
| NO20064297L (no) | Aminoalkoholforbindelse | |
| JP2017503760A5 (cg-RX-API-DMAC7.html) | ||
| MA33501B1 (fr) | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) | |
| JP2021501756A5 (cg-RX-API-DMAC7.html) | ||
| JP2019501919A (ja) | スルファミド誘導体およびその製造方法と応用 | |
| JP2006523698A5 (cg-RX-API-DMAC7.html) | ||
| JP2005533801A5 (cg-RX-API-DMAC7.html) | ||
| EA200500095A1 (ru) | Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств | |
| JP2015534567A5 (cg-RX-API-DMAC7.html) | ||
| JP2016512541A5 (cg-RX-API-DMAC7.html) | ||
| RU2010116779A (ru) | Производное амида индазолакриловой кислоты |